Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
Lantern Pharma received a USPTO Notice of Allowance for a patent covering methods to treat ovarian, liver, kidney, and thyroid cancers using LP-184 based on a specific three-gene biomarker signature. The patent claims cover the use of PTGR1, PTPN14, and ASPH expression levels to identify patients likely to respond to the company's lead asset.
Key figures
- Trial patients
- 63
- Disease control rate
- 45%
- Trial patients responding
- 29
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.